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1607-551X/Copyright ª 2015, KaohsiuAbstract Few studies have compared percutaneous biliary stenting (PBS) and endoscopic
biliary stenting (EBS) in terms of long-term effects on cholangiocarcinoma (CC), and few have
systematically evaluated outcome associations in Taiwan. This study aimed to compare long-
term outcomes between two treatments for unresectable CC: PBS and EBS. After propensity
score matching (PSM) to reduce the effect of selection bias, 1002 CC patients were included
in this analysis: 501 in the PBS group and 501 in the EBS group. The Kaplan-Meier method
was used to construct the survival curve for all CC patients, and the Cox proportional hazards
model was used for multivariate assessment of outcome predictors. After PSM, group compar-
isons revealed a significantly longer length of stay in the PBS group compared to the EBS group
(25 days vs. 19 days, respectively; p < 0.001). Hospital costs were also significantly higher in
the PBS group than in the EBS group (US$126,575 vs. US$89,326, respectively; p < 0.001). The
median survival time was 3.7 months in all CC patients, 3.5 months in the PBS group, and 4.0
months in the EBS group. The 1-year, 3-year, and 5-year survival rates were 17.6%, 6.1%, and
3.2% in all CC patients; 16.6%, 4.8%, and 3.2% in the PBS group; and 18.6%, 7.27%, and 3% in the
EBS group, respectively. The most important predictor of survival is extrahepatic CC. Medical
professionals and healthcare providers should carefully consider the use of EBS for initial treat-
ment of obstructive jaundice in patients with unresectable CC.
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Comparison of EBS and PBS for unresectable CC 371IntroductionCholangiocarcinoma (CC) is a potentially lethal malignancy
of the liver characterized by gradual infiltration and spread
along the biliary tract. Prolonged local progression before
diagnosis is common [1].
Most CC patients present with an unresectable tumor in
an advanced stage in which prognosis is poor. Although
surgical resection is currently the only potentially curative
treatment [1], resection can only be performed in an esti-
mated 13e55% of all cases [2e5]. Cohort comparisons
indicate that CC patients who receive surgery alone or
surgery combined with adjuvant radiotherapy show survival
improvement compared to CC patients who receive no
treatment [6].
Patients with CC often present late in the course of the
disease and with signs of biliary obstruction. Death is more
likely to result from recurrent or refractory biliary
obstruction and intractable sepsis rather than from
metastasis.
Biliary stenting is a common palliative treatment for
malignant biliary obstruction. Major technological advances
in endoscopic or percutaneous stenting for unresectable CC
have been achieved in recent decades [7e10].
Clinical outcome comparisons of stenting treatment with
surgical treatment and with surgical palliative treatment
include Shaib et al. [11], who reported that older patients
and patients recently diagnosed with CC are more likely to
receive endoscopic palliation. However, there was no dif-
ference in survival between surgical and endoscopic
palliation.
Few previous studies have compared percutaneous
biliary stenting (PBS) and endoscopic biliary stenting (EBS)
in terms of survival patterns. Additionally, no studies have
longitudinally compared PBS and EBS in terms of long-term
effects on CC, and none have systematically evaluated
outcome associations in Taiwan.
To establish effective policies and to improve the effi-
ciency of medical care, clinical decision makers require a
clear understanding of the different outcomes achieved by
PBS and EBS for unresectable CC in Taiwan. Thus, the aim of
this population-based study was to provide a comparison of
long-term outcomes between PBS and EBS groups in a
population of patients with unresectable CC.
Materials and methods
Ethics statement and study population
This study analyzed administrative claims data obtained
from the Taiwan Bureau of National Health Insurance
(BNHI). Because the BNHI is the sole payer of health in-
surance claims in Taiwan, the BNHI data set was assumedly
the most comprehensive and reliable data source for the
study. The BNHI registry database also contains contracted
medical facilities and board-certified physicians as well as
monthly summaries for all inpatient claims. Although this
study was exempt from full review by the internal review
board, because it only analyzed aggregate secondary data
without identifying specific patients, the study protocol
conformed to the ethical standards established by the 1964Declaration of Helsinki, which waives the requirement for
written or verbal patient consent in data linkage studies.
The diagnostic codes included in the International
Classification of Diseases, 9th Revision, Clinical Modification
(ICD-9-CM) were used to screen patient records in the BNHI
data set. The National Health Insurance Research Database
sample included all cases of patients hospitalized after a
principal diagnosis of CC (ICD-9-CM codes 155.1, 156.1,
156.8, and 156.9) during the years 1996e2009. The enroll-
ment criterion in this study was a history of biliary tract
stenting treatment for unresectable CC. Figure 1 shows that
11,343 patients met this initial criterion. Of these, the
following patients were excluded: patients who received no
further treatment (n Z 2885) and patients who received
resection following chemotherapy and/or radiotherapy
(n Z 5758). Of the remaining 2700 patients included in the
analysis, those who had received biliary stenting treatment
after percutaneous biliary drainage were classified into the
PBS group (ICD-9-CM codes 51.98, 51.99, n Z 2199), and
those who had received biliary stenting treatment after
endoscopic biliary drainage were classified into an EBS
group (ICD-9-CM codes 51.1, 51.5, 51.64, 51.87, n Z 501).Potential confounders
The patient characteristics analyzed in this Taiwan popu-
lation of unresectable CC patients included age, sex,
Charlson Comorbidity Index (CCI) score, treatment type,
and tumor site. The CCI score was classified as 0, 1e2, and
3. Treatment type included stenting only, stenting with
chemotherapy, stenting with radiotherapy, and stenting
with chemotherapy and radiotherapy. A CC tumor origi-
nates in the ductular epithelium of the biliary tree, either
in the liver (intrahepatic CC) or, more commonly, in the
extrahepatic bile ducts (extrahepatic CC, e.g., Klatskin
tumor).Statistical analysis
The unit of analysis in this study was the individual unre-
sectable CC patient. The values compared between the PBS
and EBS groups were expressed in terms of sample size
(percentage) or median [interquartile range, (IQR)].
Continuous variables were tested for statistical significance
by one-way analysis of variance, and categorical variables
were tested using Fisher exact analysis.
To reduce the effects of selection bias during hypothesis
testing, propensity score matching (PSM) was performed
using the model developed by Rosenbaum and Rubin. In
PSM, covariates that may be present in an observational
study are replaced with variables. The characteristics used
to generate a propensity score for each patient were age,
sex, CCI score, treatment type, and tumor site. Patients in
the PBS group were then matched with patients in the EBS
group at a ratio of 1:1. After PSM, the final analysis included
1002 patients: 501 in the PBS group and 501 in the EBS
group.
The Kaplan-Meier method was used to construct the
survival curve for all CC patients, and log-rank test was
used to compare survival between the PBS group and the
Figure 1. Flowchart of study procedure. ICD-9-CMZ International Classification of Diseases, 9th Revision, Clinical Modification.
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for multivariate assessment of outcome predictors.
Statistical analyses were performed using SPSS version
18.0 (SPSS Inc., Chicago, IL, USA). All tests were two-sided,
and p values < 0.05 were considered statistically
significant.Results
Table 1 compares the PBS group and the EBS group before
and after PSM. Before PSM, the two groups significantly
differed (p < 0.05) in treatment type and tumor site. After
PSM, no variables significantly differed between the two
groups.
After PSM, the median [IQR] length of stay (LOS) was
significantly higher in the PBS group compared to the EBS
group (25 days [14e43] and 15 days [9e29], respectively).
The LOS was also significantly longer in the PBS group than
in the EBS group (p < 0.001; Table 2). The median [IQR]
total hospital treatment cost was significantly higher in the
PBS group (US$126,575 [76,771e239,515]) compared to the
EBS group (US$89,326 [53,341e164,577]). Hospital costs
were also significantly higher in the PBS group compared to
the EBS group (p < 0.001). Additionally, after PSM, the
median survival time was 3.7 months (IQR 7.2 months) in all
CC patients, 3.5 months (IQR 6.8 months) in the PBS group,
and 4.0 months (IQR 7.6 months) in the EBS group. The
respective 1-year, 3-year, and 5-year survival rates were as
follows: 17.6%, 6.1%, and 3.2% for all CC patients; 16.6%,
4.8%, and 3.2% for the PBS group; and 18.6%, 7.2%, and 3.0%
for the EBS group, respectively (Figure 2). Survival did notsignificantly differ between the PBS group and the EBS
group (p Z 0.371).
Analyses of medical resource utilization (Table 3)
showed that patients with high CCI scores had significantly
longer LOS (p < 0.001) and significantly higher hospital
costs (pZ 0.004) compared to patients with low CCI scores.
Patients who had received combined therapy had signifi-
cantly longer hospital stays (p < 0.001) and significantly
higher hospital costs (p < 0.001) compared to patients who
had not received combined therapy. Finally, hospital costs
were significantly higher in patients who had extrahepatic
CC compared to patients who did not (p Z 0.028).
Table 4 shows the survival risk factors for all patients
who had received biliary stenting treatment. Cox multi-
variate logistic analysis indicated that the independent risk
factors for all CC patients were advanced age [hazard ratio
(HR) Z 1.01, p < 0.001], high CCI score (HR Z 1.04,
p < 0.003), and extrahepatic CC (HRZ 1.35, p < 0.001). In
the PBS group, the survival risk factors were advanced age
(HR Z 1.01, p < 0.001) and extrahepatic CC (HR Z 1.37,
pZ 0.002). In the EBS group, the survival risk factors were
CCI score (HR Z 1.05, p Z 0.03) and extrahepatic CC
(HRZ 1.31, pZ 0.01). In the PBS group, combined therapy
did not achieve significantly better outcomes (HR Z 0.68,
p Z 0.05).Discussion
This study showed that, for all CC patients, the median sur-
vival timewas 3.7months, and the 1-year, 3-year, and 5-year
survival rates were 19.6%, 6.15%, and 3.2%, respectively. The
Table 1 Characteristics of the study population before and after propensity score matching (PSM).
Variables Before PSM After PSM
PBS
(n Z 2199)
EBS
(n Z 501)
p PBS
(n Z 501)
EBS
(n Z 501)
p
n % n % n % n %
Age (y)
<50 165 7.50 34 6.79 0.671 37 7.4 34 6.8 0.873
50e65 561 25.51 117 23.35 123 24.6 117 23.4
65e75 644 29.29 152 30.34 141 28.1 152 30.3
>75 829 37.70 198 39.52 200 39.9 198 39.5
Sex
Female 987 44.88 216 43.11 0.486 206 41.1 216 43.1 0.565
Male 1212 55.12 285 56.89 295 58.9 285 56.9
Charlson Comorbidity Index (score)
0 55 2.50 15 2.99 0.773 19 3.8 15 3.0 0.759
1e2 205 9.32 49 9.78 51 10.2 49 9.8
>2 1939 88.18 437 87.23 431 86.0 437 87.2
Treatment type
Stent only 1797 81.72 435 86.83 0.014 435 86.8 435 86.8 > 0.99
Stent with chemotherapy 176 8.00 36 7.19 36 7.2 36 7.2
Stent with radiotherapy 167 7.59 19 3.79 19 3.8 19 3.8
Stent with chemotherapy and radiotherapy 59 2.68 11 2.20 11 2.2 11 2.2
Tumor site
Intrahepatic 1713 77.90 329 65.67 <0.001 329 65.7 329 65.7 > 0.99
Extrahepatic 486 22.10 172 34.33 172 34.3 172 34.3
EBS Z endoscopic biliary stent; PBS Z percutaneous biliary stent.
Table 2 Comparison of length of stay and total hospital treatment cost between the percutaneous biliary stent (PBS) group
and endoscopic biliary stent (EBS) group after propensity score matching.
Variables PBS EBS p
Length of stay (d) 25 [14e43] 15 [9e29] <0.0001
Total hospital treatment cost (US$) 126,575 [76,771e239,515] 89,326 [53,341e164,577] <0.0001
Data are presented as median [interquartile range].
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consistent with the 3.9 months reported in Park et al. [12],
who evaluated survival time and prognostic factors in pa-
tients with advanced unresectable CC.
Studies of long-term outcomes of biliary stenting treat-
ment have reported widely varying survival times. For
example, reported survival times range from 2.7 months to
8.7 months after PBS [13e17] and from 2.0 months to 19.0
months after EBS [11,15,18e21]. The likely explanation for
these variations is the use of an insufficient sample size in a
case control study design.
The median survival time observed in the PBS group in
the current study was consistent with the 3.7 months re-
ported by Pinol et al. [15] in an earlier prospective ran-
domized clinical trial. The median survival time in the EBS
group (120 days) was also consistent with that obtained in a
population-based study by Shaib et al. [11] (122 days).
In this study, the difference in the median survival time
between the PBS group and the EBS group did not reach
statistical significance. In a case control study by Paik et al.
[17], the median survival times were 8.7 months in the PBSgroup and 6.2 months in EBS group. Similarly, the differ-
ence was not statistically significant (p Z 0.125).
In contrast with Paik et al. [17], our study revealed a
longer median survival time in the EBS group compared to
the PBS group (4.0 months vs. 3.5 months, respectively),
although the difference did not reach statistical signifi-
cance (p Z 0.371).
Singhal et al. [22] suggested that, since EBS has a low
procedure-related complication rate, it is probably the
preferred treatment modality. However, PBS can poten-
tially obtain equally satisfactory results and is a good
alternative when endoscopy has failed or is unavailable, or
in cases of multiple isolated segments with cholangitis.
Regarding medical resource utilization, hospital cost was
significantly higher in the PBS group compared to the EBS
group (US$126,575 vs. US$89,326, respectively; p < 0.001).
The median LOS was also significantly higher in the PBS
group compared to the EBS group (25 days vs. 19 days,
respectively; p < 0.001). The median LOS of 25 days ob-
tained for the PBS group in this study was consistent with
the median LOS reported by Sut et al. [23] in a long-term
Figure 2. Comparison of overall survival between PBS group and EBS group after propensity score matching. EBS Z endoscopic
biliary stenting; IQR Z interquartile range; PBS Z percutaneous biliary stenting; SD Z standard deviation.
Table 3 Multiple linear regression of length of stay and total hospital treatment cost.
Variablesa Length of stay Total hospital treatment cost
Unstandardized
coefficient
Standardized
coefficient
p Unstandardized
coefficient
Standardized
coefficient
p
Age 0.01 0.02 0.570 0.01 0.02 0.410
Sex 0.04 0.01 0.860 0.01 0.01 0.970
Charlson Comorbidity Index (score) 0.02 0.12 <0.001 0.01 0.09 0.004
Treatment type
Stent with chemotherapy 0.31 0.21 <0.001 0.27 0.19 <0.001
Stent with radiotherapy 0.30 0.15 <0.001 0.34 0.17 <0.001
Stent with chemotherapy and radiotherapy 0.65 0.24 <0.001 0.68 0.27 <0.001
Tumor site 0.04 0.05 0.110 0.05 0.07 0.028
R2 Z 0.23, adjusted R2 Z 0.22 R2 Z 0.20, adjusted R2 Z 0.19
a Reference: sex (female), treatment type (stent only), tumor site (intrahepatic).
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drainage for palliation of malignant biliary obstruction. The
median LOS of 19 days obtained for the EBS group in the
current study was also consistent with the median LOS of 20
days reported by Smith et al. [20] in a randomized trial of
endoscopic stenting treatment for malignant lower bile
duct obstruction.
In another randomized clinical trial, Pinol et al. [15]
demonstrated that, in terms of the treatment actually
administered, the cost of percutaneous stent placement is
significantly higher than the cost of endoscopic prosthesisplacement with respect to either the initial admission or
the overall treatment.
Prognostic factors for unresectable CC treated with
biliary stenting are rarely reported in the literature. In this
study, Cox multivariate regression analysis of independent
risk factors for all CC patients were age (HR Z 1.01,
p < 0.01), CCI score (HR Z 1.04, p Z 0.003), and extra-
hepatic CC (HR Z 1.35, p < 0.001). In the PBS group, the
independent risk factors were age (HR Z 1.31, p Z 0.01)
and CCI score (HRZ 1.05, pZ 0.03). In the EBS group, the
independent risk factor was extrahepatic CC (HR Z 1.31,
Table 4 Survival analysis using stepwise Cox multivariate regression.
Variablesa After propensity score matching
Total (n Z 1002) PBS group (n Z 501) EBS group (n Z 501)
HR (95% CI) p HR (95% CI) p HR (95% CI) p
Age 1.01 (1.01e1.02) <0.001 1.01 (1.01e1.02) <0.001 1.01 (1.00e1.02) 0.080
Sex 0.91 (0.80e1.03) 0.150 0.95 (0.79e1.15) 0.600 0.86 (0.72e1.03) 0.110
Charlson Comorbidity Index (score) 1.04 (1.01e1.08) 0.003 1.05 (1.00e1.09) 0.300 1.05 (1.01e1.09) 0.030
Treatment type
Stent with chemotherapy 0.79 (0.60e1.03) 0.080 0.68 (0.46e0.99) 0.050 0.92 (0.64e1.34) 0.680
Stent with radiotherapy 0.86 (0.62e1.19) 0.360 0.91 (0.57e1.45) 0.680 0.81 (0.50e1.29) 0.370
Stent with chemotherapy and radiotherapy 0.68 (0.44e1.04) 0.080 0.58 (0.32e1.08) 0.090 0.82 (0.45e1.51) 0.520
Tumor site 1.35 (1.17e1.56) <0.001 1.37 (1.12e1.68) 0.002 1.31 (1.07e1.61) 0.010
CI Z confidence interval; EBS Z endoscopic biliary stent; HR Z hazard ratio; PBS Z percutaneous biliary stent.
a Reference: sex (female), treatment type (stent only), tumor site (intrahepatic).
Comparison of EBS and PBS for unresectable CC 375pZ 0.01). Extrahepatic CC is the most important predictor
of survival, whereas advanced age and high CCI score are
negative prognostic indicators. Our results are consistent
with Brountzos et al. [24], who showed that, bilirubin level,
age, and presence of Bismuth type IV lesion were inde-
pendent predictors of survival. In Guglielmi et al. [25], an
analysis of long-term outcomes of resectable CC revealed
that intrahepatic CC had a longer survival rate compared to
perihilar CC.
Many population-based cancer studies have also re-
ported that the presence of a comorbidity is associated
with poor prognosis [26e28].
A retrospective study by Ferna´ndez-Ruiz et al. [29]
further investigated the use of comorbidities for predict-
ing survival in CC patients. They found that a high comor-
bidity level (CCI score  2) was significantly associated with
a lower survival compared to the remainder of the cohort,
and the effect was independent of other prognostic
variables.
Table 4 shows that the patients who had received com-
bined chemotherapy and radiotherapy had a better prog-
nosis compared to patients who had received only
chemotherapy or only radiotherapy. However, the differ-
ence did not reach statistical significance (Table 4). In a
prospective study by Andrasina et al. [30], favorable prog-
noses were achieved by a complex tailored oncological
therapy comprising stent, brachytherapy, and chemo-
therapy. Another retrospective analysis revealed that, for
unresectable hilar CC, a multimodal approach combining
percutaneous stenting with radiotherapy and chemo-
therapy is an effective alternative to palliative surgery
[31].
The limitations must be considered when interpreting
the findings of this study. First, despite the use of PSM to
correct for inadequacies in this observational study, the
clinical picture obtained by analyzing claims data is not as
precise as that obtained by analyzing prospective clinical
trial data, due to possible errors in the coding of primary
diagnoses and surgical modalities. Another noted limitation
is that the data analysis did not include some important and
well-established prognostic indicators (e.g., laboratory
data, cancer stage, etc.) for unresectable CC treated by
PBS or EBS. Third, the literature on biliary stenting forunresectable CC agrees that metallic stents provide a
longer patency period, better drainage, and longer survival
compared to plastic stents [32e34]. However, the analysis
in this study did not consider stent type, because coverage
by the Taiwan National Health Insurance System does not
include the cost of metallic stents. Therefore, the findings
may not be generalizable to patients who receive metallic
stenting treatment. Fourth, the analysis did not examine
outcome data such as patient-reported quality of life and
indirect costs incurred after discharge. However, given the
robust magnitude of the effects and the statistical signifi-
cance of the effects in this study, these limitations are
unlikely to compromise the results.
In conclusion, negative prognostic indicators in patients
with unresectable CC include advanced age, multiple
comorbidities, and extrahepatic CC. This population-based
comparison of PBS and EBS in a cohort of CC patients
indicated that EBS provides a shorter LOS and a lower total
hospital treatment cost. The EBS also provides better sur-
vival compared to PBS, although the difference is not sta-
tistically significant. Therefore, medical professionals and
healthcare providers should carefully consider the use of
EBS for initial treatment of obstructive jaundice in patients
with unresectable CC.References
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